يحاول ذهب - حر

Cough syrup tragedy: Lessons learnt!

October 23, 2025

|

Chronicle Pharmabiz

THE Diethylene Glycol (DEG) poisoning occurred from using contaminated cough syrup has already claimed twenty-four children in several states in India.

- Dr Guru Prasad Mohanta, Abhilasha Mohanta & K. Shailaja

The blame game continues accusing from one to the other as responsible for this tragic incident It is not that the DEG poisoning occurred for the first time, the first incident occurred in America in 1937 when a company used DEG as solvent for preparing sulfanilamide elixir in an attempt to develop paediatric product as it was not soluble in water.

Unfortunately, more than one hundred children lost their lives before the product was withdrawn. This unfortunate incident led to enactment of Federal Food, Drugs and Cosmetic Act of 1938 and creation of FDA to administer and enforce the Act.

The DEG poisoning continues to be an issue in India despite several poisoning cases reported over the years and no major initiatives taken to prevent similar occurrence. Fortunately, at this time India seems to have awaken and something to be done is in everybody's mind from manufacturer to regulators. We have been always reactive rather than proactive.

Let us look into the few serious issues involved in this case. The company is given manufacturing licence by the Tamil Nadu government but the products are used in other states. The other state's concerned authority writes back to Tamil Nadu authority seeking help. That means the authorities are different when handling. Madhya Pradesh government formed special investigating team (SIT) to look into the whole issue of cough syrup related deaths. The different state governments have different capacities both in terms of adequacy number of officers and their capacity to implement the provision of the Drugs and Cosmetics Act.

Though, the regulatory mechanisms are based on the same act but implementation is different. The drug regulatory authorities failed to monitor the activities of the firm. It has been reported that the manufacturing pharma of this killer pharma was not inspected for over a decade or so. The inspection is a monitoring mechanism.

المزيد من القصص من Chronicle Pharmabiz

Chronicle Pharmabiz

Chronicle Pharmabiz

Home-grown CAR-T cell therapies gaining ground

INDIAN biotech and pharmaceutical companies are actively working on innovative solutions to make CART cell therapy both accessible and cost-effective.

time to read

4 mins

November 27, 2025

Chronicle Pharmabiz

NPPA extends price fixation on orthopaedic implants for 1 year

IN a move that will disappoint the industry, the National Pharmaceutical Pricing Authority (NPPA) has extended the ceiling price fixation it imposed on orthopaedic knee implants for knee replacement system for one more year.

time to read

1 mins

November 27, 2025

Chronicle Pharmabiz

FICCI envisages it's Smart AAMs to boost healthcare

In line with the Central Government's vision of comprehensive primary healthcare, FICCI Swasth Bharat Task Force has undertaken a transformative initiative titled 'Smart Ayushman Arogya Mandirs-AAMs' (earlier called Health & Wellness Centres) aimed at strengthening the primary healthcare delivery system across India.

time to read

1 min

November 27, 2025

Chronicle Pharmabiz

DoP asked to bring policy for affordable drug pricing

THE Parliamentary Panel on Chemicals and Fertilisers has recommended to the Department of Pharmaceutical (DoP) to take steps to come out with a pharmaceutical policy with thrust to provide both scheduled and nonscheduled formulations at affordable prices.

time to read

1 mins

November 27, 2025

Chronicle Pharmabiz

Ramaiah emphasises need for bone health and osteoporosis diagnosis

RAMAIAH Memorial Hospital (RMH), a multi-superspecialty quaternary care hospitals emphasises on bone health and osteoporosis diagnosis. It calls for timely screening and diagnosis through the new and advanced DXA scanner with superior and accurate test results.

time to read

2 mins

November 27, 2025

Chronicle Pharmabiz

Nathealth calls for action in 2026-27 Union Budget

NATHEALTH has submitted its budget 2026-27 recommendations to the Union government, outlining a roadmap to strengthen healthcare delivery, foster innovation, and expand insurance and preventive coverage.

time to read

1 mins

November 27, 2025

Chronicle Pharmabiz

Hotspots & growth opportunities in biomanufacturing

THE Indian bioeconomy has grown from US$ 10 billion in 2014 to US$ 165.7 billion in 2024, and is likely reach US$ 300 billion by 2030.

time to read

3 mins

November 27, 2025

Chronicle Pharmabiz

Omega Hospitals acquires Cytecare Hospitals

Morgan Stanley PE backed Hyderabad-based Omega Hospitals has acquired Cytecare Hospitals, a leading cancer care hospital in Bengaluru.

time to read

2 mins

November 27, 2025

Chronicle Pharmabiz

Devices sector hails withdrawal of QCOs

THE medical devices manufacturers industry in the country has welcomed the Central government's decision to withdraw multiple Quality Control Orders (QCOs) imposed on essential raw materials across various industries, including the medical devices sector.

time to read

1 min

November 27, 2025

Chronicle Pharmabiz

'There is urgent need for tech-focused regulatory approach for med devices'

THE Indian healthcare industry has evolved at a breakneck pace, but its regulatory framework has struggled to keep up to its speed of development.

time to read

2 mins

November 27, 2025

Listen

Translate

Share

-
+

Change font size